VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | Bone marrow as a superior source of stem cells after PTCy-based haplo-HSCT

Vanderson Rocha, MD, Fundação Pró-Sangue Hemocentro de São Paulo & Universidade de São Paulo, Sao Paulo, Brazil, discusses findings from a meta-analysis comparing peripheral blood versus bone marrow as a source of stem cells after haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PTCy). Using bone marrow reduced rates of mortality and graft-versus-host disease (GvHD). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter